While we evaluated the expression of CXCR3 on 20 out of 30 patient samples (including seven patients with stage I, nine patients with stage II, and four patients with stage III) due to resource limitations, investigating the level of expression per cell (based on normalized mean fluorescent intensity, MFI) revealed that NK cells from patients with BC express CXCR3 significantly more than HDs. This evidence concerns the gene CXCR3 and breast cancer.